Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2022 - 2025)

Zentalis Pharmaceuticals has reported Non-Current Assets over the past 4 years, most recently at $35.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $35.8 million for Q4 2025, down 19.19% from a year ago — trailing twelve months through Dec 2025 was $156.0 million (down 22.17% YoY), and the annual figure for FY2025 was $35.8 million, down 19.19%.
  • Non-Current Assets for Q4 2025 was $35.8 million at Zentalis Pharmaceuticals, down from $38.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ZNTL hit a ceiling of $104.4 million in Q1 2022 and a floor of $35.8 million in Q4 2025.
  • Median Non-Current Assets over the past 4 years was $54.3 million (2023), compared with a mean of $62.0 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 42.62% in 2023 and later dropped 9.48% in 2024.
  • Zentalis Pharmaceuticals' Non-Current Assets stood at $87.4 million in 2022, then plummeted by 37.09% to $55.0 million in 2023, then dropped by 19.46% to $44.3 million in 2024, then dropped by 19.19% to $35.8 million in 2025.
  • The last three reported values for Non-Current Assets were $35.8 million (Q4 2025), $38.9 million (Q3 2025), and $40.1 million (Q2 2025) per Business Quant data.